Can Immunopeptidomics Redefine Cancer Immunotherapy Development?

• by Katherine Tran

• November 3, 2026

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

• by Adam D. Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P. Laubach, Sheeba K. Thomas, Simon J. Harrison, Luciano J. Costa, Andrew Spencer, Rafael Fonseca, Peter A. Forsberg, Jesus G. Berdeja, Rayan Kaedbey, Nizar J. Bahlis, Paula Rodriguez-Otero, Maria-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong, James Cooper, Amrita Krishnan

• October 20, 2026

The Evidence-Based Cancer Control Programs website – a strategy for disseminating effective interventions

• by Aubrey Villalobos, Jennifer Damonte, David A. Chambers

• October 23, 2026

Rising Endometrial Cancer Incidence: Clinical Priorities in Evaluation and Management

The increasing incidence of endometrial cancer is placing greater emphasis on timely recognition of abnormal uterine bleeding, individualized risk assessment and prompt diagnostic evaluation.

• by

• October 21, 2026

• 6 min